A new drug has shown promise in combating Parkinson’s disease while minimizing unwanted side effects.

Two studies published in Nature found stem cell-derived products can not only be safely transplanted into the brain, but also ...

The highly selective partial agonist at D1 and D5 receptors significantly improves motor function in patients recently ...

For patients with Parkinson's disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to levodopa increases total daily ON time ...

SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not ...

BRIDGEWATER, N.J., April 03, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today ...

Parkinson’s is a neurodegenerative disease, meaning it impacts neurotransmitters in the brain. It affects muscle movements in ...

Until now, levodopa has been the standard first-line treatment for Parkinson’s patients. Levodopa — which is converted into dopamine in the brain and targets the D2/D3/D4 dopamine receptors ...

have added CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD) to their national prescription drug formularies. CREXONT is a prescription ...